- Home
- PRVA vs NAMS Comparison
PRVA vs NAMS Comparison
Compare PRVA & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | NAMS |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRVA | NAMS |
|---|---|---|
| Price | $23.78 | $35.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $30.07 | ★ $46.40 |
| AVG Volume (30 Days) | 709.5K | ★ 1.0M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,042,569,000.00 | $35,243,000.00 |
| Revenue This Year | $103.35 | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | $169.12 | ★ N/A |
| Revenue Growth | ★ 19.01 | 4.91 |
| 52 Week Low | $18.77 | $14.06 |
| 52 Week High | $26.51 | $42.00 |
Technical Indicators
Market Signals| Indicator | PRVA | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 47.82 |
| Support Level | $23.34 | $32.85 |
| Resistance Level | $24.27 | $37.00 |
| Average True Range (ATR) | 0.68 | 1.56 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 30.61 | 61.40 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.